إعلان
إعلان
NTLA
Intellia Therapeutics, Inc
10.13
USDبرعاية
+0.39
+4.04%
٠٧ يناير, ١٦:٠٠ UTC -5
مغلق
قبل الإفتتاح
10.58
+0.45
+4.41%
تقارير أرباح NTLA
النسبة الإيجابية المفاجئة
NTLA تفوق 21 من 39 آخر التقديرات.
54%
التقرير التالي
بيانات التقرير القادم
٢٥ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$13.04M
/-$0.97
التغير الضمني من Q3 25 (Revenue/ EPS)
-5.36%
/+5.43%
التغير الضمني من Q4 24 (Revenue/ EPS)
+1.31%
/-23.62%
Intellia Therapeutics, Inc earnings per share and revenue
On ٠٦ نوفمبر ٢٠٢٥, NTLA reported earnings of -0.92 USD per share (EPS) for Q3 25, beating the estimate of -1.02 USD, resulting in a 9.97% surprise. Revenue reached 13.78 مليون, compared to an expected 15.49 مليون, with a -11.02% difference. The market reacted with a -22.73% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 23 المحللين forecast an EPS of -0.97 USD, with revenue projected to reach 13.04 مليون USD, implying an زيادة of 5.43% EPS, and نقصان of -5.36% in Revenue from the last quarter.
الأسئلة الشائعة
What were Intellia Therapeutics, Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Intellia Therapeutics, Inc reported EPS of -$0.92, beating estimates by 9.97%, and revenue of $13.78M, -11.02% below expectations.
How did the market react to Intellia Therapeutics, Inc's Q3 2025 earnings?
The stock price moved down -22.73%, changed from $12.32 before the earnings release to $9.52 the day after.
When is Intellia Therapeutics, Inc expected to report next?
The next earning report is scheduled for ٢٥ فبراير ٢٠٢٦.
What are the forecasts for Intellia Therapeutics, Inc's next earnings report?
Based on 23
المحللين, Intellia Therapeutics, Inc is expected to report EPS of -$0.97 and revenue of $13.04M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان